Randomized phase 11 trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma
1998

Study on Biochemotherapy for Metastatic Melanoma

Sample size: 65 publication Evidence: moderate

Author Information

Author(s): SRD Johnston, DO Constenlal, J Moore, H Atkinson, RP A'Hern, G Dadian, PG Riches, ME Gore

Primary Institution: Royal Marsden NHS Trust

Hypothesis

Does the addition of interferon alpha and interleukin 2 to biochemotherapy improve outcomes in patients with metastatic melanoma?

Conclusion

The addition of interferon alpha and interleukin 2 to biochemotherapy did not improve response rates in patients with metastatic melanoma and increased some treatment-related toxicity.

Supporting Evidence

  • The overall response rate for BCDT with IL-2/IFN-α was 23%, while for BCDT alone it was 27%.
  • Median survival was 5 months for BCDT with IL-2/IFN-α and 5.5 months for BCDT alone.
  • Patients receiving biochemotherapy experienced a higher incidence of severe thrombocytopenia (37% vs 13%).
  • Despite immune activation, the addition of IL-2 and IFN-α did not improve treatment outcomes.

Takeaway

Doctors wanted to see if adding special medicines to cancer treatment would help patients with melanoma, but it didn't make things better and caused more side effects.

Methodology

Patients were randomized to receive either biochemotherapy with IL-2 and IFN-α or chemotherapy alone, and their responses were measured after treatment.

Potential Biases

Potential bias in patient selection and treatment assignment.

Limitations

The study had a small sample size and may not be generalizable to all patients with metastatic melanoma.

Participant Demographics

Patients aged 18 to 70 with metastatic melanoma, good performance status, and no more than one previous chemotherapy.

Statistical Information

P-Value

0.03

Confidence Interval

95% CI 10-40%

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication